188 related articles for article (PubMed ID: 26284587)
1. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis.
Perez-Janices N; Blanco-Luquin I; Torrea N; Liechtenstein T; Escors D; Cordoba A; Vicente-Garcia F; Jauregui I; De La Cruz S; Illarramendi JJ; Coca V; Berdasco M; Kochan G; Ibañez B; Lera JM; Guerrero-Setas D
Oncotarget; 2015 Sep; 6(27):23944-58. PubMed ID: 26284587
[TBL] [Abstract][Full Text] [Related]
2. RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer.
Guerrero-Setas D; Pérez-Janices N; Blanco-Fernandez L; Ojer A; Cambra K; Berdasco M; Esteller M; Maria-Ruiz S; Torrea N; Guarch R
Mod Pathol; 2013 Aug; 26(8):1111-22. PubMed ID: 23542458
[TBL] [Abstract][Full Text] [Related]
3. Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma.
Guo W; Dong Z; Cui J; Guo Y; Shen S; Guo X; Kuang G
Clin Exp Metastasis; 2016 Jan; 33(1):73-85. PubMed ID: 26482475
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.
Conway K; Edmiston SN; May R; Kuan PF; Chu H; Bryant C; Tse CK; Swift-Scanlan T; Geradts J; Troester MA; Millikan RC
Breast Cancer Res; 2014 Oct; 16(5):450. PubMed ID: 25287138
[TBL] [Abstract][Full Text] [Related]
5. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
6. EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.
Perez-Janices N; Blanco-Luquin I; Tuñón MT; Barba-Ramos E; Ibáñez B; Zazpe-Cenoz I; Martinez-Aguillo M; Hernandez B; Martínez-Lopez E; Fernández AF; Mercado MR; Cabada T; Escors D; Megias D; Guerrero-Setas D
Oncotarget; 2015 Jan; 6(1):368-80. PubMed ID: 25621889
[TBL] [Abstract][Full Text] [Related]
7. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer.
Endoh M; Tamura G; Honda T; Homma N; Terashima M; Nishizuka S; Motoyama T
Br J Cancer; 2005 Dec; 93(12):1395-9. PubMed ID: 16265349
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
9. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.
Cooper WN; Dickinson RE; Dallol A; Grigorieva EV; Pavlova TV; Hesson LB; Bieche I; Broggini M; Maher ER; Zabarovsky ER; Clark GJ; Latif F
Oncogene; 2008 Mar; 27(12):1805-11. PubMed ID: 17891178
[TBL] [Abstract][Full Text] [Related]
11. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Barrio-Real L; Benedetti LG; Engel N; Tu Y; Cho S; Sukumar S; Kazanietz MG
Breast Cancer Res; 2014 Sep; 16(5):441. PubMed ID: 25248717
[TBL] [Abstract][Full Text] [Related]
12. Basal-like breast cancer displays distinct patterns of promoter methylation.
Lee JS; Fackler MJ; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Sukumar S
Cancer Biol Ther; 2010 Jun; 9(12):1017-24. PubMed ID: 20505321
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Shen S; Guo X; Kuang G; Yang Z
Mol Carcinog; 2016 Nov; 55(11):1655-1666. PubMed ID: 26456015
[TBL] [Abstract][Full Text] [Related]
16. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
17. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
Blows FM; Driver KE; Schmidt MK; Broeks A; van Leeuwen FE; Wesseling J; Cheang MC; Gelmon K; Nielsen TO; Blomqvist C; Heikkilä P; Heikkinen T; Nevanlinna H; Akslen LA; Bégin LR; Foulkes WD; Couch FJ; Wang X; Cafourek V; Olson JE; Baglietto L; Giles GG; Severi G; McLean CA; Southey MC; Rakha E; Green AR; Ellis IO; Sherman ME; Lissowska J; Anderson WF; Cox A; Cross SS; Reed MW; Provenzano E; Dawson SJ; Dunning AM; Humphreys M; Easton DF; García-Closas M; Caldas C; Pharoah PD; Huntsman D
PLoS Med; 2010 May; 7(5):e1000279. PubMed ID: 20520800
[TBL] [Abstract][Full Text] [Related]
18. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.
Gharanei S; Brini AT; Vaiyapuri S; Alholle A; Dallol A; Arrigoni E; Kishida T; Hiruma T; Avigad S; Grimer R; Maher ER; Latif F
Epigenetics; 2013 Sep; 8(9):893-8. PubMed ID: 23887284
[TBL] [Abstract][Full Text] [Related]
19. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
